First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT05086315
Trial Phases:	Phase I Phase II	Protocol IDs:	TCD17197 (primary) NCI-2021-12677 2021-004287-98 U1111-1266-7399
Eligibility:	1 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Sanofi Aventis
NCI Full Details:	http://clinicaltrials.gov/show/NCT05086315

Summary

This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion
study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic
activity of SAR443579 in various hematological malignancies.

Objectives

2.5 years.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.